期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

微粒化非诺贝特的临床新进展 被引量：1

下载PDF
导出
摘要 非诺贝特是属于第二代苯氧芳酸类调脂药,除可降低血清甘油三酯水平以外,还兼有降低血清胆固醇,升高高密度脂蛋白胆固醇(HLD—C)水平等作用,因此是一种针对多种脂质异常危险因素的强有力的全面调脂药。1 非诺贝特的作用机理 非诺贝特的作用方式是与激活过氧化物酶体增殖物活化受体(peroxisome proliferator activated re-ceptor α,PPAR α)有关。PPAR α是一种细胞核内受体,通过调控与脂质代谢有关的基因的表达,参与对体内脂质代谢的调节。非诺贝特激活PPAR α后,通过几种途径参与对脂质代谢的调节:(1)抑制载脂蛋白(apo)CⅢ的合成。apo
作者 叶平
机构地区 解放军总医院老年心内科
出处 《中国医药导刊》 2000年第1期42-43,共2页 Chinese Journal of Medicinal Guide
关键词 微粒化 非诺贝特 药理 调指作用
分类号 R969 [医药卫生—药理学]
  • 相关文献

参考文献7

  • 1Farnier M,Binnefous F,Debbas N,et al.Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type Ⅱ a and Ⅱ b hyperlipidemia[].Archives of Internal Medicine.1999
  • 2Guerin M,Brucleert E,Dolphin PJ,et al.Fenofibrate reduces plasma choesteryl ester transfer from LDL to VLDL and normalizes the athetogenic dense LDL profile on combined dyslipidemia[].Arteriosclerosis and Thrombosis.1996
  • 3De la Serna G,Cadarso C.Fenofibrate decreases plasma fibrinogen and improves lipid profile and reduces uricemia[].Clinical Pharmacology and Therapeutics.1999
  • 4Adkine JC,Faulds D.Micronized fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of hyperlipidemia[].Drugs.1997
  • 5Steiner G,Stewart D,Hosking JD.Baseline characteristics of the study population in the diabetes atheosclerosis intervention study (DAIS).World Health Organization collaborating center for study of Atherosclerosis in Diabetes[].The American Journal of Cardiology.1999
  • 6Madej A,Okopion B,Kowalski J,et al.Effect of fenofibrate on plasma cytokine concentration in patients with atherosclerosis and hyperlipoproteinemia Ⅱ b[].International Journal of Clinical Pharmacology and Therapeutics.1998
  • 7Parkard CJ.Overview offeenofibrate[].European Heart Journal.1998

同被引文献15

  • 1Branchi A, Bovellini R, Sommariwa D, et al. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors in patients with primary hypercholesterolemia [J]. Thromb Heamost, 1993,70 .- 241-243.
  • 2Nilsson L, Takemura T, Eriksson P, et al. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells [J]. Arterioscler Thromb Vasc Biol,1999,19:1577-1581.
  • 3Ross R. Atherosclerosis an inflammatory disease[J]. N Engl J Med. 1999,340:115-126.
  • 4Shah PK. Plaque disruption and thrombosis: potential role of inflammation and infection[J]. Cardiol Clin, 1999,17:270-281.
  • 5Schumacher A, Seljeflot I, Sommervoll L, et al. Increased levels of markers of vascular inflammation in patients with coronary heart disease[J]. Scand J Clin Lab Invest, 2002,62 : 59- 68.
  • 6Valen G, Yan ZQ, hansson Gk. Nuclear factor kappa-B and the heart[J]. J Am Coll Cardiol, 2001,38:307-314.
  • 7Wilson SH, Best PJ, Edwards WS, et al. Nuclear factor kappa-B immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectors[J]. Atherosclerosis, 2002,161 : 147-153.
  • 8Delerive P, Gervois P, Fruchart JC, et al. Induction of IкBα expression as a mechanism contributing to the anti-inflammatory-activities of PPARα activators[J]. J Biol Chem, 2000,275 : 36703-36707.
  • 9Delerive P, Martin Nizard F, Chinetti G, et al. PPAR activators inhibit thrombin induced endothelin 1 production in human vascular endothelial cells by inhibiting the AP-1 signaling pathway[J]. Circ Res, 1999,85:394-402.
  • 10Max N, Sukhova GK, Collins T, et al. PPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 ex pression in human endothelial cells [J]. Circulation, 1999, 99:3125-3131.

引证文献1

二级引证文献7

中国医药导刊
2000年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部